Compare Incyte Corporation (INCY) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Sprott Uranium Miners ETF — how do they compare? Incyte Corporation trades at $117.94 (market cap $23.11B), while Sprott Uranium Miners ETF trades at $49.8. The key difference: Incyte Corporation is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| INCY | URNM | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $118.52 | $83.99 |
52-Week Low | $67.38 | $44.14 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
URNM trades at $48.25, up 0.06% on the day, with technical indicators showing a bearish trend from moving averages but neutral oscillators. The ETF focuses on uranium miners, benefiting from rising nuclear energy demand driven by AI power needs. Recent news highlights strong performance, with URNM up 26% year-to-date as of April 2026, though some articles question miner valuations versus uranium prices.
The outlook for URNM is supported by long-term nuclear energy growth, but risks include volatility in uranium prices and concentrated miner exposure. Analyst sentiment is mixed, with some seeing upside from AI-driven power demand, while others caution on supply chain gaps and equity optimism diverging from fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
